You are going to a different site than you have been browsing. Click continue to visit site or close to select a site with our global language selector.
Kontrollera att sökord är rättstavade.
Prova med annat sökord.
Prova mer generella sökord.
Technology for healthier lives
We understand that delivering quality diagnostic care with the lowest possible radiation dose is a desired goal. Learn how our Dose Management solutions can help you achieve Dose Leadership.
You've earned her trust. Keep it by being a dose management leader.
Goldseal - Renoverade system
Hospital & Healthcare Solutions
DoseWatch - Dose Management Solution
GE Healthcare’s DoseWatch dose management solution can be the cornerstone of a comprehensive, proactive radiation management program.
Lösningar installerad bas
A new life for your imaging systems. Better performance for you.
Återgå till den globala sidan
Dela denna sida
Diana Salvo, MDClinical Director and Head of Institute of Nuclear MedicineAnnibale Versari, MDMSenior Clinical lecturer in Multimodality Imaging
Federica Fioroni, MSMedical PhysicistArchipedale Santa Maria NuovaReggio Emilia, ItalyThe Reggio Emilia ASMN PET Center was created in 2000. In 2002, a 10 MeV Cyclotron (Minitrace GE) was installed in order to produce clinical 18F-FDG and 18F-Choline. A protocol to produce 18FLT and 18F-MISO will also be available soon for research purpose.
Female - 57 years old - 167cm - 65kgThis patient is undergoing PET staging before surgery.29th August 2007: Whole-body PET/CT positive1st September: Whole-body bone scintigraphy negative3rd September: Sentinel lymph node positive
Scanner: GE Discovery STEPET acquisition: Whole-body acquisition
CT acquisition: Whole-body acquisition
Fused coronal view shows focal Pre-surgery VR showing axillary node 3Duptake in right axillary node position and primary lesion
Axial fused view of the primary lesion
Fused Axial view of right axillary node Fused Coronal view of right axillary node
The lesion showed by the “other modality” was confirmed in the right breast.
PET pointed out the presence of a 3mm micrometastasis in the right axillary, and changed the final staging and hence the therapy choice.